Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma

• Status: Completed
• Trial end date: 2010-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purposes of this trial are to decrease toxicity and improve treatment effectiveness elderly patients. With a short course of chemotherapy with cyclophosphamide, mitoxantrone, vincristine, and prednisone with concurrent administration of rituximab it is likely to be as effective as longer programs, and will certainly be better tolerated by this patient group. The addition of maintenance therapy may result in substantial prolongation of remission duration.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: SCRI Development Innovations, LLC
• Collaborators: Amgen; Genentech, Inc.
• Treatments: Cyclophosphamide; Mitoxantrone; Prednisone; Rituximab; Vincristine

Criteria

Inclusion Criteria:

To be included in this study, you must meet the following criteria:

• Histologically documented large B-cell, CD20-positive non-Hodgkin's lymphoma

• No previous treatment

• Clinical stage II, III, or IV by the Ann Arbor Staging Criteria

• Age > 70 years

• ECOG performance status 0, 1, or 2

• Adequate bone marrow, liver and kidney function

• Must give written informed consent prior to entering this trial

Exclusion Criteria:

You cannot participate in this study if any of the following apply to you:

• Age < 18 years

• Central nervous system involvement with lymphoma

• Coexistent active malignancies treated within five years

• Active infection precluding the use of combination chemotherapy

• HIV infection

• Pregnant or lactating

Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.